{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:39:39Z","timestamp":1781285979219,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":3235,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Norwegian Radium Hospital"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.breast.2010.05.013","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T04:35:49Z","timestamp":1276835749000},"page":"493-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival"],"prefix":"10.1016","volume":"19","author":[{"given":"Ben","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Tuft","family":"Stavnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"F\u00f8rsund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasmund","family":"Berner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Cathrine","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2010.05.013_bib1","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2010.05.013_bib2","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2010.05.013_bib3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/1097-0142(19810415)47:8<2087::AID-CNCR2820470830>3.0.CO;2-9","article-title":"Pleural effusion in breast cancer: a review of 105 cases","volume":"47","author":"Fentiman","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib4","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/1097-0142(19811201)48:11<2524::AID-CNCR2820481130>3.0.CO;2-4","article-title":"Pleural effusion in breast carcinoma: analysis of 122 cases","volume":"48","author":"Raju","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib5","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/1097-0142(19951015)76:8<1377::AID-CNCR2820760813>3.0.CO;2-M","article-title":"Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute","volume":"76","author":"Wilkes","year":"1995","journal-title":"Cancer (Phila)"},{"key":"10.1016\/j.breast.2010.05.013_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/1097-0142(19870715)60:2<263::AID-CNCR2820600225>3.0.CO;2-N","article-title":"Pericardial effusion in women with breast cancer","volume":"60","author":"Buck","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib7","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/1097-0142(19881115)62:10<2226::AID-CNCR2820621026>3.0.CO;2-D","article-title":"Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences","volume":"62","author":"Kamby","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-07-4478","article-title":"Endoglin (CD105): a marker of tumor vasculature and potential target for therapy","volume":"14","author":"Dallas","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2010.05.013_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10456-008-9101-9","article-title":"Endoglin in angiogenesis and vascular diseases","volume":"11","author":"ten Dijke","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.breast.2010.05.013_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2010.05.013_bib11","doi-asserted-by":"crossref","first-page":"176.e1","DOI":"10.1016\/j.ajog.2007.03.036","article-title":"Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia","volume":"197","author":"Staff","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.breast.2010.05.013_bib12","first-page":"856","article-title":"Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis","volume":"59","author":"Kumar","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2010.05.013_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1309\/1KF54L6RB625556W","article-title":"CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients","volume":"119","author":"Dales","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2010.05.013_bib14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/sj.bjc.6603491","article-title":"The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer","volume":"95","author":"Beresford","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib15","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1158\/1078-0432.CCR-07-4214","article-title":"Vascularization in primary breast carcinomas: its prognostic significance and\u00a0relationship with tumor cell dissemination","volume":"14","author":"Dhakal","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2010.05.013_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M","article-title":"Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer","volume":"89","author":"Li","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib17","first-page":"524","article-title":"Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2010.05.013_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-008-0261-5","article-title":"Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy","volume":"119","author":"Vo","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2010.05.013_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2407-6-231","article-title":"Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer","volume":"6","author":"Zhou","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib20","doi-asserted-by":"crossref","first-page":"533.e1","DOI":"10.1016\/j.ajog.2008.04.004","article-title":"Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary","volume":"199","author":"\u00d8degaard","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.breast.2010.05.013_bib21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/00000478-200111000-00008","article-title":"The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells","volume":"25","author":"Davidson","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.breast.2010.05.013_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejogrb.2004.11.015","article-title":"Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia","volume":"122","author":"Staff","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.breast.2010.05.013_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/B:BREA.0000010704.17479.8a","article-title":"Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma","volume":"83","author":"Davidson","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2010.05.013_bib24","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1158\/1078-0432.CCR-04-0183","article-title":"Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression","volume":"10","author":"Davidson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2010.05.013_bib25","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.20946","article-title":"Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma","volume":"103","author":"Elloul","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-005-7328-3","article-title":"Angiogenic molecule expression is downregulated in effusions from breast cancer patients","volume":"94","author":"Konstantinovsky","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2010.05.013_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00428-005-0144-7","article-title":"Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma","volume":"449","author":"Kleinberg","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.breast.2010.05.013_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2006.01.034","article-title":"The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma","volume":"102","author":"Davidson","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.breast.2010.05.013_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1309\/E899BG1282M5D505","article-title":"Survivin, a member of the inhibitors of apoptosis (IAP) family, is down-regulated in breast carcinoma effusions","volume":"128","author":"Kleinberg","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2010.05.013_bib30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1524-4741.2008.00625.x","article-title":"The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions","volume":"14","author":"Davidson","year":"2008","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2010.05.013_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.lungcan.2008.12.007","article-title":"Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control","volume":"65","author":"Hsu","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib32","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.rmed.2008.07.008","article-title":"Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions","volume":"102","author":"Duysinx","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.breast.2010.05.013_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000135689","article-title":"The local cytokine and chemokine milieu within malignant effusions","volume":"29","author":"Atanackovic","year":"2008","journal-title":"Tumour Biol"},{"key":"10.1016\/j.breast.2010.05.013_bib34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","article-title":"Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease","volume":"85","author":"Kraft","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/thx.54.8.707","article-title":"Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions","volume":"54","author":"Thickett","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.breast.2010.05.013_bib36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.breast.2010.05.013_bib37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10585-004-3150-2","article-title":"Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma","volume":"21","author":"Davidson","year":"2004","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.breast.2010.05.013_bib38","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1378\/chest.118.6.1747","article-title":"Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions","volume":"118","author":"Cheng","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.breast.2010.05.013_bib39","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.1996.593","article-title":"Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma","volume":"74","author":"Altomonte","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2010.05.013_bib40","first-page":"213","article-title":"Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms","volume":"73","author":"Henriksen","year":"1995","journal-title":"Lab Invest"},{"key":"10.1016\/j.breast.2010.05.013_bib41","first-page":"371","article-title":"Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies","volume":"5","author":"Matsuno","year":"1999","journal-title":"Clin Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977610001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977610001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:26:55Z","timestamp":1760776015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977610001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0960977610001451"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2010.05.013","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2010.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}